Centrum Zdrowia MDM
- Address
- lock Available on a paid plan
Congenital, Hereditary, and Neonatal Diseases
The Department of Hepatology‑Gastroenterology at Centrum Zdrowia MDM is conducting studies aimed at improving treatment for Classic Congenital Adrenal Hyperplasia, a hereditary hormonal disorder. Researchers are evaluating a new oral agent to reduce glucocorticoid exposure while maintaining adrenal androgen control.
- Assessment of adrenal hormone balance
- Glucocorticoid‑sparing therapeutic strategies
- Safety and tolerability of novel endocrine compounds
These investigations reflect the site’s dedication to advancing care for patients with rare congenital conditions in Warsaw.
Digestive System Diseases
Clinical research at Centrum Zdrowia MDM focuses on inflammatory bowel disorders such as Crohn's disease and ulcerative colitis, testing innovative biologic and oral agents to induce remission and maintain long‑term disease control.
- Biologic therapy optimization for moderate to severe disease
- Oral small‑molecule induction and maintenance regimens
- Long‑term safety and quality‑of‑life outcomes
The program aims to expand therapeutic options for patients across Europe who struggle with chronic intestinal inflammation.
Hormonal Diseases
The site’s endocrine research explores novel approaches to manage hormonal imbalances, including the use of targeted agents to improve adrenal function in Congenital Adrenal Hyperplasia and related disorders.
- Evaluation of receptor‑modulating compounds
- Strategies to minimize lifelong steroid dependence
- Patient‑reported outcome measures for endocrine health
By integrating endocrinology within its gastroenterology department, the center seeks to provide comprehensive care for hormonal disease patients.
Otorhinolaryngologic Diseases
Investigators at Centrum Zdrowia MDM are evaluating a single‑dose middle‑ear injection for Idiopathic Sudden Sensorineural Hearing Loss, aiming to improve hearing recovery compared with standard oral steroids.
- Middle‑ear drug delivery technology
- Audiometric improvement metrics
- Rapid‑onset therapeutic interventions
The trial supports the center’s commitment to advancing otolaryngology treatments for acute hearing emergencies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Crinetics Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Zdrowia MDM
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, multicenter phase 3 study in patients with moderately to severely active ulcerative colitis (UC) to compare the efficacy, safety and immunogenicity of PB016 and Entyvio® for the induction and maintenance of clinical response and remission. (UCESIVE) | Polpharma Biologics S.A. | Phase III | Not Recruiting | Nov 2023 | Apr 2026 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 6-Fluoro-9-Methyl-9H-Pyrido[3,4-B]-Indole | 1 | Unknown | 2022-08-08 | 2022-08-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.